Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat Thrombocytopenias in the U.S.

July 9, 2008
Further evidence that government intervention is around the corner
By a GLG Expert Contributor
Analysis of: Pricey Drugs Put Squeeze on Doctors (online.wsj.com)
Chemotherapy drugs are so costly that not only are the patients unable to pay co-pays, but oncologists are laying out hundreds of thousands of dollars with only a promise they will be reimbursed.
July 8, 2008
What ever happens I can assure you the Doctors will be f........
By a GLG Expert Contributor
Analysis of: Clash on Preventing Cut to Doctor Payments (online.wsj.com)
11% drop in physician re-imbursement vs HMO sponsored Medicare "advantage" programs. Who will win out?
July 7, 2008
Cost vs Efficacy: A conundrum for insurers, physicians and patients.
By a GLG Expert Contributor
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma (www.nytimes.com)
Extraordinarily expensive Avastin makes all think twice before using, due to ?? efficacy data as well as questions re: quality of life v survival benefits.
July 3, 2008
Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
By a GLG Expert Contributor
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (content.nejm.org)
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
July 3, 2008
Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
By a GLG Expert Contributor
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer (content.nejm.org)
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
June 30, 2008
The heck with the impact on Roche. How about the patients??
By a GLG Expert Contributor
Analysis of: Roche decision denies cancer drug to Britons (www.ft.com)
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
June 30, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
By a GLG Expert Contributor
Analysis of: Medicare fees to doctors fall Tuesday (news.yahoo.com)
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
June 27, 2008
The other shoe falls II: Amgen and J & J will not be happy.
By a GLG Expert Contributor
Analysis of: Europe Backs Anemia-Drug Warnings (online.wsj.com)
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
June 26, 2008
Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
By a GLG Expert Contributor
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty (content.nejm.org)
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
June 23, 2008
Amgen as well as J & J: Adding insult to injury......
By a GLG Expert Contributor
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents (www.medscape.com)
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 445

Analytics


Generated at 2009-01-07T13:00:17.563